Medical Grade Sodium Hyaluronate Market Size, Share & Forecast Analysis to 2030

The global medical grade sodium hyaluronate market size was valued at around 5 billion in 2025 and expected to grow at a significant CAGR of around 6% during the forecast period from 2026 to 2030. The market is driven by rising demand for ophthalmic surgeries, osteoarthritis treatments, and minimally invasive medical procedures. The North America is expected to maintain a dominant market position, supported by advanced healthcare infrastructure, high healthcare expenditure, and strong demand for ophthalmic and orthopedic treatments.

Market Sapshot:

Key Insights:

• Increasing demand for ophthalmic surgeries and orthopedic treatments is strengthening the adoption of medical-grade sodium hyaluronate across healthcare applications.
• Intra-articular injections represent a key product category, supported by their use in viscosupplementation treatments for knee osteoarthritis.
• Ophthalmology remains an important application area due to sodium hyaluronate use in ophthalmic viscoelastic devices, eye lubricants, and surgical formulations.
• North America benefits from advanced healthcare infrastructure and established medical technologies, while Asia Pacific offers growth potential through expanding healthcare access and manufacturing capabilities.

Key Factors Driving the Medical Grade Sodium Hyaluronate Market Growth

The increasing prevalence of ophthalmic disorders and growing demand for surgical procedures are key factors driving the medical grade sodium hyaluronate market. The sodium hyaluronate is widely used in ophthalmic viscoelastic devices to protect eye tissues and maintain space during procedures such as cataract surgery. Its growing use in orthopedic treatments, particularly intra-articular injections for knee osteoarthritis, also supports market demand. An aging population, rising healthcare expenditure, and the increasing adoption of minimally invasive medical treatments are further contributing to the expansion of medical-grade sodium hyaluronate applications.

The market is further driven by the continuous advancements in hyaluronic acid-based medical products and the growing demand for effective osteoarthritis treatments. In January 2026, Fidia Pharma USA announced the commercial availability of HYMOVIS® ONE in the United States, following FDA premarket approval in April 2025. The product is a single-injection hyaluronan hydrogel indicated for knee osteoarthritis pain in eligible patients. Such product innovations are expanding treatment options, encouraging the adoption of advanced sodium hyaluronate formulations, and supporting market growth.

Kye Growth Drivers:

• Increasing demand for ophthalmic surgeries, particularly cataract procedures, is driving the use of medical-grade sodium hyaluronate in ophthalmic viscoelastic devices.
• The rising prevalence of osteoarthritis, an aging population, and growing demand for orthopedic treatments are supporting the adoption of sodium hyaluronate-based injections.
• Advancements in fermentation-based manufacturing, injectable hydrogels, drug delivery systems, and advanced wound care products are expanding medical applications and creating new growth opportunities.

Growth Opportunities in the Global Medical Grade Sodium Hyaluronate Market

The medical grade sodium hyaluronate market offers growth opportunities through expanding applications in medical aesthetics, ophthalmology, regenerative medicine, and advanced wound care. Manufacturers can benefit from rising demand for high-purity, fermentation-derived sodium hyaluronate by developing specialized formulations, improving production efficiency, and expanding into emerging markets. The growing use of injectable hyaluronic acid products for skin hydration and other medical applications is also creating opportunities for product innovation and portfolio diversification.

In June 2026, China’s Zhejiang Jingjia Medical Technology received approval from the National Medical Products Administration (NMPA) for its sodium hyaluronate solution for injection, designed to temporarily improve facial skin dryness and dullness in adults. The product uses microbial fermentation technology and expands the company’s medical aesthetics portfolio. This development highlights opportunities for manufacturers to introduce specialized sodium hyaluronate-based injectable products and strengthen their presence in the growing medical aesthetics market.

Key Growth Opportunities:

• Expanding applications in regenerative medicine, advanced wound care, and drug delivery systems are creating opportunities for manufacturers to develop innovative sodium hyaluronate-based medical products.
• Growing demand for minimally invasive aesthetic procedures and injectable hyaluronic acid formulations is opening new avenues for product innovation and portfolio expansion.
• Increasing adoption of fermentation-derived, high-purity sodium hyaluronate and expanding healthcare infrastructure in emerging economies are creating opportunities to improve production scalability and strengthen market penetration.

Industry Trends Shaping the Global Medical Grade Sodium Hyaluronate Market

The medical grade sodium hyaluronate market is witnessing a shift toward high-purity biomaterials, cross-linked formulations, and specialized injectable products designed for orthopedic care, ophthalmology, and medical aesthetics. Manufacturers are increasingly focusing on improved product stability, longer-lasting formulations, and advanced fermentation technologies to meet stringent quality requirements and expand the clinical applications of sodium hyaluronate. These trends are also encouraging investment in research, product differentiation, and regulatory compliance.

In September 2026, Singclean Medical announced that its Medical Sodium Hyaluronate Gel for Bone Joint received CE certification under the European Union Medical Device Regulation (EU MDR 2017/745), supporting its expansion into European orthopedic markets. The certification highlights the growing importance of regulatory compliance, clinical evaluation, and quality management in the development of sodium hyaluronate-based medical devices. This trend may encourage manufacturers to strengthen product development and pursue international market access.

Market Segments Insights:

By Product Type: The Intra-articular Injections Segment Dominated the Global Medical Grade Sodium Hyaluronate Market

The global medical grade sodium hyaluronate market is bifurcated into product type, form, source, application, end user, and geography. On the basis of product type, the intra-articular injections segment is expected to account for a significant share of the market, driven by the rising prevalence of osteoarthritis, an aging population, and increasing demand for non-surgical joint pain management options. Sodium hyaluronate is used in viscosupplementation injections, particularly for knee osteoarthritis, to supplement joint fluid and improve lubrication. Growing awareness of minimally invasive treatment options and continued development of hyaluronic acid-based injectable formulations are further supporting demand for medical-grade sodium hyaluronate in orthopedic applications.

The established clinical use of sodium hyaluronate in knee osteoarthritis treatment supports the importance of this segment. For example, the U.S. Food and Drug Administration (FDA) has approved HYALGAN for treating knee osteoarthritis pain in patients who have not responded adequately to conservative non-pharmacological therapy and simple analgesics. This regulatory approval demonstrates the recognized medical application of sodium hyaluronate-based injections and supports their continued presence in orthopedic care. However, clinical recommendations vary, and the American Academy of Orthopaedic Surgeons does not recommend hyaluronic acid injections for routine use in symptomatic knee osteoarthritis.

By Application: The Ophthalmology Sub-category Holds the Largest Share of the Global Medical Grade Sodium Hyaluronate Market

On the basis of application, the medical grade sodium hyaluronate market is further segmented into ophthalmology, orthopedics, dermatology, cosmetic surgery, drug delivery, wound healing, and others. The ophthalmology segment is a key application segment in the market, driven by the widespread use of sodium hyaluronate in ophthalmic viscoelastic devices, artificial tears, and eye lubricants. Its viscoelastic and moisture-retention properties help protect ocular tissues during cataract surgery and support the management of dry eye conditions. Growing demand for cataract procedures, an aging population, and advancements in ophthalmic surgical products are expected to support segment growth.

A recent clinical study published in July 2026 in Ophthalmology and Therapy compared two sodium hyaluronate-based ophthalmic viscoelastic devices used during cataract surgery. The study involved 140 patients and reported that both products maintained surgical space, with no observed adverse events or intraoperative complications during the study. This research highlights ongoing clinical evaluation and product development in sodium hyaluronate-based ophthalmic devices, supporting continued innovation in this application area.

Global Medical Grade Sodium Hyaluronate Market Segmentation:

By Product Type:

• Intra-Articular Injections
• Ophthalmic Viscoelastic Devices
• Dermal Fillers
• Anti-Adhesion Products
• Wound Care Products
• Scaffold Materials
• Others

By Form:

• Injectable
• Topical
• Eye Drops
• Gel
• Surgical Devices

By Source:

• Fermentation-Derived
• Animal-Derived
• Others

By Application:

• Ophthalmology
• Orthopedics
• Dermatology
• Cosmetic Surgery
• Drug Delivery
• Wound Healing
• Others

By End-User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Pharmaceutical and Biotechnology Companies
• Research Laboratories

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The North America Leading the Global Medical Grade Sodium Hyaluronate Market

Geographically, the North America is a key region in the medical grade sodium hyaluronate market, supported by advanced healthcare infrastructure, high healthcare expenditure, and strong demand for ophthalmic, orthopedic, and aesthetic treatments. The U.S. Centers for Disease Control and Prevention (CDC) stated that the 18.9% of U.S. adults aged 18 and older had diagnosed arthritis in 2022, with prevalence increasing to 53.9% among adults aged 75 and older. This substantial arthritis burden highlights the need for joint-related healthcare solutions and supports demand for orthopedic treatments, including sodium hyaluronate-based products.

The Europe maintains a strong presence due to established healthcare systems, advanced medical technologies, and demand for ophthalmic and orthopedic treatments. Meanwhile, Asia Pacific offers significant growth potential, supported by expanding healthcare infrastructure, rising medical procedure volumes, and manufacturing capabilities in China, Japan, and India. Latin America and the Middle East and Africa also present opportunities as access to specialized healthcare improves. These factors support the wider adoption of medical-grade sodium hyaluronate across ophthalmology, orthopedics, wound care, and medical aesthetics.

Competitive Analysis:

The medical grade sodium hyaluronate market is characterized by competition among established pharmaceutical ingredient manufacturers, biotechnology companies, and medical product developers. The key players include Bloomage Biotech, HTL Biotechnology, Contipro, Seikagaku Corporation, Kewpie Corporation, Lifecore Biomedical, and Fidia Farmaceutici. These companies compete through product purity, manufacturing quality, molecular weight customization, regulatory compliance, and research and development capabilities. For example, Kewpie Corporation supplies pharmaceutical-grade sodium hyaluronate for injections, eye drops, and external preparations, while Seikagaku Corporation supplies high-purity hyaluronic acid for orthopedic and ophthalmic applications.

The competition is increasingly focused on fermentation-based manufacturing, specialized pharmaceutical-grade formulations, and expansion into high-value medical applications. The Bloomage Biotech has developed sodium hyaluronate products for pharmaceutical and medical device applications, including orthopedics and ophthalmology, while Contipro emphasizes pharmaceutical-grade sodium hyaluronate produced through bacterial fermentation under established quality standards. The companies that strengthen quality assurance, expand production capabilities, maintain regulatory certifications, and establish partnerships with pharmaceutical and medical device manufacturers are well positioned to compete in this market.

Key Companies:

• Bloomage Biotechnology Corporation Limited
• HTL Biotechnology
• Contipro
• Kewpie Corporation
• Lifecore Biomedical
• Seikagaku Corporation
• Shandong Focusfreda Biotech Co., Ltd.
• Shandong Topscience Biotech Co., Ltd.
• Fidia Farmaceutici
• Kikkoman Biochemifa Company
• Shandong AWA Biopharm Co., Ltd.
• Altergon Italia S.r.l.

Global Medical Grade Sodium Hyaluronate Market Outlook

• Rising demand for ophthalmic surgeries and osteoarthritis treatments will support medical-grade sodium hyaluronate adoption across healthcare applications.
• Expanding medical aesthetics and dermal filler procedures will create opportunities for innovative sodium hyaluronate formulations and specialized injectable products.
• Advancements in fermentation technology will improve sodium hyaluronate purity, manufacturing consistency, production efficiency, and pharmaceutical-grade product availability.
• Growing research into drug delivery, regenerative medicine, and wound healing will expand sodium hyaluronate applications across advanced healthcare and biomaterial technologies.
• Asia Pacific will offer significant growth opportunities through expanding healthcare infrastructure, increasing medical procedures, and established pharmaceutical manufacturing capabilities.